Phreesia (NYSE:PHR) Insider Sells $21,883.20 in Stock

Key Points

• Yvonne Hui, an insider at Phreesia, sold 940 shares at an average price of $23.28, which decreased her position by 2.98%, leaving her with a total of 30,638 shares valued at approximately $713,252.64.
• Phreesia's stock recently traded up to $24.28 and has experienced a 52-week range with a low of $17.07 and a high of $32.76.
• Analysts have issued price targets for Phreesia, with estimates ranging from $32.00 to $36.00, suggesting a generally optimistic outlook on the company’s performance.

Phreesia, Inc. (NYSE:PHR - Get Free Report) insider Yvonne Hui sold 940 shares of the business's stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total value of $21,883.20. Following the completion of the transaction, the insider directly owned 30,638 shares in the company, valued at approximately $713,252.64. This trade represents a 2.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Yvonne Hui also recently made the following trade(s):

• On Friday, July 18th, Yvonne Hui sold 626 shares of Phreesia stock. The shares were sold at an average price of $26.23, for a total transaction of $16,419.98.
• On Thursday, July 17th, Yvonne Hui sold 465 shares of Phreesia stock. The shares were sold at an average price of $26.89, for a total transaction of $12,503.85.
• On Wednesday, July 16th, Yvonne Hui sold 422 shares of Phreesia stock. The stock was sold at an average price of $26.95, for a total transaction of $11,372.90.
• On Tuesday, July 15th, Yvonne Hui sold 307 shares of Phreesia stock. The shares were sold at an average price of $27.27, for a total transaction of $8,371.89.
• On Monday, July 7th, Yvonne Hui sold 571 shares of Phreesia stock. The shares were sold at an average price of $28.85, for a total transaction of $16,473.35.

Phreesia Stock Up 3.6%

Shares of PHR traded up $0.87 during trading hours on Monday, hitting $24.74. The stock had a trading volume of 1,065,169 shares, compared to its average volume of 1,230,749. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $32.76. The firm has a market capitalization of $1.48 billion, a P/E ratio of -58.90 and a beta of 0.72. The firm has a 50 day simple moving average of $27.51 and a 200-day simple moving average of $26.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.12 and a quick ratio of 2.12.

Phreesia (NYSE:PHR - Get Free Report) last released its quarterly earnings data on Thursday, September 4th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.08. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The firm had revenue of $117.26 million during the quarter, compared to the consensus estimate of $116.39 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. The company's quarterly revenue was up 14.9% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. Sell-side analysts predict that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on PHR shares. Citigroup reaffirmed an "outperform" rating on shares of Phreesia in a research note on Monday, September 8th. Truist Financial raised their price target on shares of Phreesia from $35.00 to $36.00 and gave the company a "buy" rating in a research report on Friday, September 5th. Raymond James Financial set a $33.00 price objective on Phreesia and gave the stock an "outperform" rating in a report on Friday, September 5th. Wall Street Zen raised Phreesia from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. Finally, DA Davidson raised Phreesia to a "strong-buy" rating in a research report on Monday, September 8th. One research analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, Phreesia presently has an average rating of "Buy" and a consensus target price of $34.08.

Institutional Trading of Phreesia

A number of hedge funds have recently bought and sold shares of PHR. Raymond James Financial Inc. increased its position in shares of Phreesia by 2.7% during the 2nd quarter. Raymond James Financial Inc. now owns 14,049 shares of the company's stock valued at $400,000 after purchasing an additional 375 shares during the last quarter. Diversified Trust Co boosted its holdings in shares of Phreesia by 1.0% in the 2nd quarter. Diversified Trust Co now owns 45,042 shares of the company's stock worth $1,282,000 after buying an additional 426 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Phreesia by 2.8% during the second quarter. PNC Financial Services Group Inc. now owns 19,983 shares of the company's stock valued at $569,000 after buying an additional 540 shares during the period. Arcadia Investment Management Corp MI increased its holdings in Phreesia by 0.7% during the first quarter. Arcadia Investment Management Corp MI now owns 92,770 shares of the company's stock worth $2,371,000 after buying an additional 615 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. raised its position in Phreesia by 9.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 8,803 shares of the company's stock worth $251,000 after acquiring an additional 792 shares during the period. 92.10% of the stock is currently owned by institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.